Brenntag Specialties Inc. (BSI) Expands Pharmaceutical, Over-the-Counter (OTC), and Personal Care Product Offering with Novo Nordisk Pharmatech A/S

NJ, USA and Koege, Denmark:- Brenntag Specialties, Inc. (BSI) and Novo Nordisk Pharmatech A/S have entered into a distribution agreement for Pharmaceutical Grade Quaternary Ammonium Compounds into the Pharmaceutical, Over-the-Counter (OTC), and Personal Care Markets in the United States & Puerto Rico.

“The partnership with Novo Nordisk Pharmatech demonstrates our commitment to providing innovative solutions and differentiated value to our customers by strategically expanding our principal relationships and product lines.” said Jeff Kenton, President of Brenntag Specialties, Inc. “The product line offering from Novo Nordisk Pharmatech furthers our reach into the pharmaceutical, OTC, and personal care markets.”

Novo Nordisk Pharmatech manufactures its Pharmaceutical Grade Quaternary Ammonium Compounds in accordance with the highest cGMP standards in the market- the ICH Q7A Guide for Active Pharmaceutical Ingredients.

The new product offering includes:

• FeF ™ Benzalkonium Chloride and Cetrimide solutions
• FeF ™ Benzalkonium Chloride 95%
• Crystalline FeF ™ Cetrimide and FeF ™ (CTAB) Cetyl Trimethyl Ammonium Bromide

An innovative synthesis process makes Novo Nordisk Pharmatech a leading supplier of crystalline quaternary ammonium compounds. They have excellent antimicrobial and surface-active properties rendering them suitable for a variety of applications. High levels of purity make them particularly suited for specialized pharmaceutical applications, such as polysaccharide vaccine production and precipitation of DNA (gene therapy) vaccines. Quaternary ammonium compounds act either as preservatives or active ingredients in many ophthalmic, nasal, oral and topical drugs and in a variety of surgical scrubs, medicated solutions, ointments and creams.

Novo Nordisk Pharmatech manufactures quaternary ammonium compounds using only high-purity tertiary amines with various alkyl chain lengths, normally ranging from C12 to C18. The properties of our quaternary ammonium compounds can vary according to the alkyl chain length, but they all offer common attributes including:

• Proven record of efficacy against a broad spectrum of microorganisms
• Effective through a wide pH range
• Odourless and colourless in product formulation
• Surface active / adhesive cationic agent
• Very stable, proven under ICH Q1 Stability Protocols
• Five-year shelf life
• Drug Master Files available for reference

About Brenntag

Brenntag, the global market leader in chemical distribution, covers all major markets with its extensive product and service portfolio. Headquartered in Mülheim an der Ruhr, Germany, the company operates a global network with more than 530 locations in 74 countries. In 2015, the company, which has a global workforce of more than 14,000 employees, generated sales of EUR 10.3 billion (USD 11.5 billion). Brenntag connects chemical manufacturers and chemical users.

The company supports its customers and suppliers with tailor-made distribution solutions for industrial and specialty chemicals. With over 10,000 products and a world-class supplier base, Brenntag offers one-stop-shop solutions to around 180,000 customers. This includes specific application technology, an extensive technical support and value-added services such as just-in-time delivery, product mixing, formulation, repackaging, inventory management and drum return handling. Long-standing experience and local excellence in the individual countries characterize the global market leader for chemical distribution.

About Novo Nordisk Pharmatech A/S

Novo Nordisk Pharmatech A/S was established in 1949 as FeF Chemicals, acquired by Novo Nordisk in 1986 and has been part of the pharmaceutical group since then. On 1 September 2015 the company’s name was changed to Novo Nordisk Pharmatech A/S. It is the leading worldwide supplier of recombinant insulin for cell growth media and pharmaceutical grade quaternary ammonium compounds (Quats) for the pharmaceutical, biopharmaceutical and personal care industries

The company markets its diabetic care, hemophilia, growth hormone therapy, obesity, and hormone replacement therapy (HRT) products worldwide, with customers in more than 180 countries.

For Financial Year 2015, Novo Nordisk reported world sales totaling 107,927 million Danish kroner (DEK) with more than half of all sales recorded in North America.